ProMACE-CytaBOM regimen: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen; ProMACE-CytaBOM Regimen...") |
No edit summary |
||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of a non-cross resistant regimen consisting of [[prednisone]], [[methotrexate]], [[doxorubicin]], [[cyclophosphamide]] and [[etoposide]] (ProMACE) alternating with [[cytarabine]], [[bleomycin]], [[vincristine|vincristine (oncovin)]] and [[methotrexate]] (CytaBOM), used to treat aggressive forms of [[non-Hodgkin lymphoma|non-Hodgkin's lymphoma]]<ref name="pmid15459544">{{cite journal| author=Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y et al.| title=Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy. | journal=Dermatology | year= 2004 | volume= 209 | issue= 3 | pages= 243-5 | pmid=15459544 | doi=10.1159/000079901 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15459544 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63460&ns=NCI_Thesaurus}}</ref> | {{PAGENAME}} refers to a regimen consisting of a non-cross resistant regimen consisting of [[prednisone]], [[methotrexate]], [[doxorubicin]], [[cyclophosphamide]] and [[etoposide]] (ProMACE) alternating with [[cytarabine]], [[bleomycin]], [[vincristine|vincristine (oncovin)]] and [[methotrexate]] (CytaBOM), used to treat aggressive forms of [[non-Hodgkin lymphoma|non-Hodgkin's lymphoma]]<ref name="pmid15459544">{{cite journal| author=Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y et al.| title=Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy. | journal=Dermatology | year= 2004 | volume= 209 | issue= 3 | pages= 243-5 | pmid=15459544 | doi=10.1159/000079901 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15459544 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63460&ns=NCI_Thesaurus}}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|Pro|Prednisone}} | {{chemo|Pro|Prednisone}} | ||
{{chemo|M|Methotrexate}} | {{chemo|M|Methotrexate}} | ||
{{chemo|A|Doxorubicin (Adriamycin)}} | {{chemo|A|Doxorubicin (Adriamycin)}} | ||
| Line 27: | Line 28: | ||
==Indications== | ==Indications== | ||
*[[Non-Hodgkin lymphoma]]<ref name="pmid15459544">{{cite journal| author=Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y et al.| title=Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy. | journal=Dermatology | year= 2004 | volume= 209 | issue= 3 | pages= 243-5 | pmid=15459544 | doi=10.1159/000079901 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15459544 }} </ref | *[[Non-Hodgkin lymphoma]]<ref name="pmid15459544">{{cite journal| author=Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y et al.| title=Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy. | journal=Dermatology | year= 2004 | volume= 209 | issue= 3 | pages= 243-5 | pmid=15459544 | doi=10.1159/000079901 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15459544 }} </ref | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Revision as of 19:11, 27 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen; ProMACE-CytaBOM Regimen
Overview
ProMACE-CytaBOM regimen refers to a regimen consisting of a non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine (oncovin) and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin's lymphoma[1][2]
Regimen
ProPrednisone
MMethotrexate
ADoxorubicin (Adriamycin)
CytaCyclophosphamide
EEtoposide
CytaCytarabine
BBleomycin
OVincristine (Oncovin)
MMethotrexate
Indications
- Non-Hodgkin lymphoma<ref name="pmid15459544">Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y; et al. (2004). "Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy". Dermatology. 209 (3): 243–5. doi:10.1159/000079901. PMID 15459544. </ref
References
- ↑ Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y; et al. (2004). "Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy". Dermatology. 209 (3): 243–5. doi:10.1159/000079901. PMID 15459544.
- ↑ "NCI Thesaurus".